CAS 1005780-62-0

Formule : C23H23N7O3

InChI : InChI=1S/C23H23N7O3/c1-13-4-7-16(11-17(13)24-23(32)18-10-14(2)27-29(18)3)33-21-9-8-20-25-19(12-30(20)28-21)26-22(31)15-5-6-15/h4,7-12,15H,5-6H2,1-3H3,(H,24,32)(H,26,31)

Code InChI : DZFZXPPHBWCXPQ-UHFFFAOYSA-N

SMILES : CC1=C(C=C(C=C1)OC2=NN3C=C(N=C3C=C2)NC(=O)C4CC4)NC(=O)C5=CC(=NN5C)C

TAK-593

CAS : 1005780-62-0

Formule : C₂₃H₂₃N₇O₃

Degré de pureté : 98%

Masse moléculaire : 445.4738

Ref: IN-DA008TJS

TAK-593

CAS : 1005780-62-0

TAK-593

Formule : C₂₃H₂₃N₇O₃

Degré de pureté : 99%

Masse moléculaire : 445.47

Ref: 54-BUP09817

TAK-593

CAS : 1005780-62-0

TAK-593 is an effective VEGFR and PDGFR family inhibitor (IC50s: 3.2, 0.95, 1.1, 4.3, and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα, and PDFGRβ, respectively).

Formule : C₂₃H₂₃N₇O₃

Degré de pureté : 99.37%

Couleur et forme : Solid

Masse moléculaire : 445.4738

Ref: TM-T16975

TAK-593

CAS : 1005780-62-0

TAK-593 is an activator of the N-terminal signaling domain of the erythropoietin receptor that is selective for the erythropoietin receptor. It inhibits tumor growth and induces apoptosis in cancer cells by inhibiting protein synthesis. TAK-593 has been shown to induce tumor regression in mice with lung carcinomas, prostate carcinomas, and breast carcinomas. It also prevents the development of retinal neovascularization in a rat model of oxygen-induced retinopathy and reduces intraocular pressure in rats with experimental glaucoma. TAK-593 is a potent inhibitor of angiogenesis and vascular permeability.

Formule : C₂₃H₂₃N₇O₃

Degré de pureté : Min. 95%

Masse moléculaire : 445.47 g/mol

Ref: 3D-FQB78062